104.48
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché BNTX Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$106.28
Aprire:
$106.23
Volume 24 ore:
649.49K
Relative Volume:
0.76
Capitalizzazione di mercato:
$25.12B
Reddito:
$3.13B
Utile/perdita netta:
$-381.72M
Rapporto P/E:
-65.23
EPS:
-1.6017
Flusso di cassa netto:
$-2.15B
1 W Prestazione:
-0.03%
1M Prestazione:
+2.34%
6M Prestazione:
+10.98%
1 anno Prestazione:
-11.06%
Biontech Se Adr Stock (BNTX) Company Profile
Confronta BNTX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
BNTX
Biontech Se Adr
|
104.48 | 25.55B | 3.13B | -381.72M | -2.15B | -1.6017 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
414.86 | 107.98B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
456.95 | 59.07B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
569.90 | 59.76B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
804.90 | 49.19B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
335.80 | 38.56B | 4.56B | -176.77M | 225.30M | -1.7177 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-06-05 | Reiterato | H.C. Wainwright | Buy |
2025-05-29 | Iniziato | Goldman | Neutral |
2025-03-13 | Iniziato | Citigroup | Buy |
2025-01-10 | Iniziato | Truist | Buy |
2024-12-11 | Iniziato | Wells Fargo | Overweight |
2024-12-02 | Reiterato | BMO Capital Markets | Outperform |
2024-11-19 | Iniziato | Berenberg | Buy |
2024-11-19 | Aggiornamento | Evercore ISI | In-line → Outperform |
2024-11-08 | Aggiornamento | Goldman | Neutral → Buy |
2024-09-24 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2024-09-17 | Aggiornamento | Jefferies | Hold → Buy |
2024-09-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
2024-08-07 | Aggiornamento | Deutsche Bank | Hold → Buy |
2024-08-02 | Aggiornamento | HSBC Securities | Hold → Buy |
2024-05-14 | Iniziato | Evercore ISI | In-line |
2024-02-23 | Iniziato | BMO Capital Markets | Outperform |
2024-01-05 | Iniziato | Oppenheimer | Perform |
2023-12-01 | Downgrade | JP Morgan | Neutral → Underweight |
2023-10-16 | Downgrade | HSBC Securities | Buy → Hold |
2023-07-14 | Iniziato | HSBC Securities | Buy |
2023-05-17 | Aggiornamento | Redburn | Neutral → Buy |
2022-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
2022-08-17 | Iniziato | Cowen | Market Perform |
2022-07-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
2022-07-06 | Ripresa | Canaccord Genuity | Buy |
2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
2021-12-16 | Iniziato | Morgan Stanley | Equal-Weight |
2021-11-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2021-10-22 | Iniziato | Deutsche Bank | Hold |
2021-10-07 | Iniziato | Jefferies | Hold |
2021-08-11 | Aggiornamento | Bryan Garnier | Neutral → Buy |
2021-07-19 | Ripresa | Wolfe Research | Outperform |
2021-06-16 | Downgrade | Redburn | Neutral → Sell |
2021-05-18 | Iniziato | Goldman | Neutral |
2021-05-11 | Downgrade | Bryan Garnier | Buy → Neutral |
2020-12-01 | Downgrade | BofA Securities | Buy → Neutral |
2020-08-03 | Ripresa | Berenberg | Buy |
2020-07-21 | Aggiornamento | BofA Securities | Neutral → Buy |
2020-06-30 | Downgrade | H.C. Wainwright | Buy → Neutral |
2020-05-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2020-04-28 | Downgrade | BofA/Merrill | Buy → Neutral |
2020-03-18 | Downgrade | JP Morgan | Overweight → Neutral |
2020-03-09 | Iniziato | H.C. Wainwright | Neutral |
2020-01-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2020-01-22 | Downgrade | UBS | Buy → Neutral |
2019-11-05 | Iniziato | Wolfe Research | Outperform |
2019-11-04 | Iniziato | Berenberg | Buy |
2019-11-04 | Iniziato | BofA/Merrill | Buy |
2019-11-04 | Iniziato | Canaccord Genuity | Buy |
2019-11-04 | Iniziato | JP Morgan | Overweight |
2019-11-04 | Iniziato | SVB Leerink | Outperform |
2019-11-04 | Iniziato | UBS | Buy |
Mostra tutto
Biontech Se Adr Borsa (BNTX) Ultime notizie
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead - The Globe and Mail
Why BioNTech Stock Jumped by Nearly 4% on Wednesday - The Motley Fool
Why BioNTech Stock Jumped by Nearly 4% on Wednesday - The Globe and Mail
TB Alternative Assets Ltd. Trims Stock Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
JPMorgan Chase & Co. Issues Positive Forecast for BioNTech (NASDAQ:BNTX) Stock Price - Defense World
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Baader Bank Aktiengesellschaft Acquires 9,040 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
37,500 Shares in BioNTech SE Sponsored ADR $BNTX Bought by Swedbank AB - MarketBeat
Rep. Val T. Hoyle Sells BioNTech SE Sponsored ADR (NASDAQ:BNTX) Shares - MarketBeat
Lingohr Asset Management GmbH Sells 36,209 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Clear Street Keeps Their Buy Rating on BioNTech SE (BNTX) - The Globe and Mail
Weekly Market Update: Stocks Gain 1.25%, Led by Technology and Communication Services - Morningstar
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises - Ariva
BioNTech’s New PDAC Study: A Potential Game-Changer in Cancer Treatment? - MSN
BioNTech (NASDAQ:BNTX) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Fred Alger Management LLC Sells 403,447 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Millennium Management LLC Increases Stock Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Biontech Se Adr Azioni (BNTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):